Alkermes Plc (ALKS)

$34.35 -0.30 (-0.87%)
Market Cap 5.63B
Revenue (ttm) 1.56B
Net Income (ttm) 367.07M
EPS (ttm) N/A
PE Ratio 14.63
Forward PE 27.08
Profit Margin 23.57%
Debt to Equity Ratio 0.00
Volume 1,896,000
Avg Vol 1,603,772
Day's Range N/A - N/A
Shares Out 162.61M
Stochastic %K 36%
Beta 0.62
Analysts Strong Sell
Price Target $37.64

Latest News on ALKS

Alkermes to Participate in Upcoming Investor Conferences

Feb 26, 2025, 4:00 PM EST - 10 days ago

Alkermes to Participate in Upcoming Investor Conferences

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Feb 25, 2025, 5:08 AM EST - 11 days ago

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 2:40 PM EST - 24 days ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Feb 12, 2025, 7:00 AM EST - 24 days ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Feb 5, 2025, 4:00 PM EST - 4 weeks ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:00 PM EST - 2 months ago

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 24, 2024, 9:58 AM EST - 3 months ago

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Alkermes to Participate in Two Upcoming Investor Conferences

Nov 11, 2024, 4:00 PM EST - 4 months ago

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Nov 7, 2024, 7:00 AM EST - 4 months ago

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:04 PM EDT - 4 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 7:00 AM EDT - 4 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Oct 17, 2024, 4:00 PM EDT - 5 months ago

Alkermes to Report Third Quarter Financial Results on October 24, 2024

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Sep 25, 2024, 8:00 AM EDT - 5 months ago

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Sep 23, 2024, 7:00 AM EDT - 5 months ago

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Sep 13, 2024, 7:00 AM EDT - 6 months ago

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:00 PM EDT - 6 months ago

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Aug 22, 2024, 7:00 AM EDT - 7 months ago

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 2:20 PM EDT - 8 months ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 7:00 AM EDT - 8 months ago

Alkermes plc Reports Second Quarter 2024 Financial Results

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Jul 17, 2024, 4:00 PM EDT - 8 months ago

Alkermes to Report Second Quarter Financial Results on July 24, 2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Jun 3, 2024, 7:00 AM EDT - 9 months ago

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

May 28, 2024, 7:00 AM EDT - 10 months ago

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17, 2024, 8:27 AM EDT - 10 months ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

May 14, 2024, 7:00 AM EDT - 10 months ago

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

May 2, 2024, 7:00 AM EDT - 11 months ago

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

Alkermes plc Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 11 months ago

Alkermes plc Reports First Quarter 2024 Financial Results

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Apr 24, 2024, 7:00 AM EDT - 11 months ago

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Alkermes to Report First Quarter Financial Results on May 1, 2024

Apr 17, 2024, 4:00 PM EDT - 11 months ago

Alkermes to Report First Quarter Financial Results on May 1, 2024

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 9, 2024, 4:29 PM EDT - 11 months ago

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Apr 9, 2024, 9:49 AM EDT - 11 months ago

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Apr 9, 2024, 7:00 AM EDT - 11 months ago

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Apr 8, 2024, 7:00 AM EDT - 11 months ago

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Mar 7, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 3:08 PM EST - 1 year ago

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Feb 15, 2024, 7:00 AM EST - 1 year ago

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Feb 8, 2024, 4:00 PM EST - 1 year ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage

Jan 26, 2024, 3:33 PM EST - 1 year ago

Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:00 PM EST - 1 year ago

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

Jan 3, 2024, 7:00 AM EST - 1 year ago

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

Dec 14, 2023, 6:05 AM EST - 1 year ago

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

Alkermes Completes Separation of Oncology Business

Nov 15, 2023, 7:00 AM EST - 1 year ago

Alkermes Completes Separation of Oncology Business

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate

Nov 10, 2023, 2:46 PM EST - 1 year ago

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate

Alkermes to Participate in the Jefferies London Healthcare Conference

Nov 7, 2023, 4:00 PM EST - 1 year ago

Alkermes to Participate in the Jefferies London Healthcare Conference

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

Oct 31, 2023, 5:08 PM EDT - 1 year ago

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

Alkermes plc (ALKS) Q3 2023 Earnings Call Transcript

Oct 25, 2023, 4:28 PM EDT - 1 year ago

Alkermes plc (ALKS) Q3 2023 Earnings Call Transcript

Alkermes plc Reports Third Quarter 2023 Financial Results

Oct 25, 2023, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Third Quarter 2023 Financial Results

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Oct 23, 2023, 8:00 AM EDT - 1 year ago

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Alkermes to Report Third Quarter Financial Results on October 25, 2023

Oct 18, 2023, 4:00 PM EDT - 1 year ago

Alkermes to Report Third Quarter Financial Results on October 25, 2023

Mural Oncology to Host Investor Webcast on October 17

Oct 10, 2023, 5:00 PM EDT - 1 year ago

Mural Oncology to Host Investor Webcast on October 17

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Oct 10, 2023, 7:00 AM EDT - 1 year ago

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress